4.Surgery for stage Ⅳ non-small cell lung cancer
China Oncology 2001;0(03):-
Stage Ⅳ non-small cell lung cancer should be restaged according different prognosis. Some patients with advanced NSCLC who received operative resection may be cured. Based on completely resection of primary lung cancer that no mediastinal lymphnode metastasis solitary brain metastasis or adrenal metastasis or ipsilateral lung metastasis should be considered for resection. Palliative surgery should be a part of multidisciplinary therapy for selective patients with advanced NSCLC.
5.Some problems of operative criterion of lung cancer
China Oncology 2001;0(05):-
According to very reliable data from evidence based medicine the operative guideline for lung cancer was approved. These include preoperative evaluation, the choice of operative modes, mediastinal lymphadenectomy and surgery for small cell lung cancer.
6.Current situation and thinking of the prognostic gene markers' in early-stage non-small-cell lung cancer
Cancer Research and Clinic 2010;22(9):577-580
Non-small-cell lung cancer (NSCLC) patients with the same TNM stage may suffer from large prognosis variations. Even patients with early-stage NSCLC still demonstrated lower-than-expecting survival rates after surgical resection, indicating that the current staging methods which were based on anatomy do not adequately predict outcome. Especially the insufficient growth of very early period tumors limited the prognostic prediction of anatomy characteristics, therefore studies focusing on tumor biologic characteristics were developed in order to identify prognostic gene markers. A variety of prognostic genomic models were based on microarray analysis and quantitative polymerase chain reaction (PCR) and analyzed by bioinformatics data processing. However, the prognostic gene lists reported to date overlapped poorly in the studies with similar background. To improve the cloudy situation, the research protocol should be standardized.On the other hand, instead of simple addition of several genes, sequential combination of prognostic gene markers based on signal pathway should be developed which may possess much more rationality and systematicness.
7.Effect of supernatant from bronchial carcinoma tissue and sera from patients on colony forming unit-T lymphocyte
Chinese Journal of Pathophysiology 1986;0(02):-
Effect of supernatant from bronchial carcinoma tissue, normal lung tissueand sera from patients with bronchial carcinoma on colony forming unit-T lymphocyte(CFU-TL) of patients themselves were surveyed. Fourteen blood bank donors were takenas normal control. The results showed that the mean value of growth rate of CFU-TLbefore discharging tumor load was 160.73?124.02/10~5 (X?SD). It was lower than that,(306.53?79.86/10~5) after discharging tumor load and (397.81?133.89/10~5) of normalcontrol (P
8.The development of predicting the lung cancer resistance to gemcitabine by the expression levels of RRM1
Cancer Research and Clinic 2000;0(06):-
Gemcitabine is important pyrimidine antimetabolites drug. Ribonucleotide reductase is oneof its targets whose overexpression has been observed in several gemcitabine- resistant cell lines. Meanwhile,the NSCLC patients with high RRM1 expression levels have a relatively poor survival when treated with gem-citabine. To this day, the relationship between RRM1 expression levels in peripheral blood mononuclear cellsand gemcitabine is still uncertain and it deserves further research.
9.New advances of pemetrexed (Alimta~) in the treatment of non-small-cell lung cancer
Yilong WU ; Scagliotti GIORGIO
China Oncology 2006;0(08):-
Pemetrexed is an antimetabolite antineoplastic agent that exerts its action by inhibiting three enzymes-thymidylate synthetase (TS), glycinamide ribonucleotide formyltransferase (GARFT) and dihydrofolate reductase (DHFR), which are essential for the synthesis of purine and pyrimidine. It causes arrest of tumor cells in S phase of the cell cycle, thus inhibiting their growth.Pemetrexed has been approved as first-line treatment in malignant pleural mesothelioma and second-line treatment in non-small-cell lung cancer (NSCLC). This paper summarizes the current developments in the treatment of NSCLC.
10.Identification of the reference genes' accuracy for lung tissue specimens by real-time quantitative PCR
Xiaoyan BAI ; Jiaying LIN ; Yilong WU
Cancer Research and Clinic 2010;22(3):186-188
Objective To analyze the expression stability of the three widely used reference genes β-glueuronidase (GUSB), glycera]dehydes-3-phosphate dehydrogenase (GAPDH), β2-microglobulin (β2-M) in Chinese lung cancer tissue specimens and normal lung tissue specimens. Methods Gene expression wasmeasured by quantitative real time PCR and expression stability was analyzed with two widely used softwares genorm and normfinder. Results The intra-and inter-group difference of GAPDH is maximum (The intra and inter-group s is 1.07 and 0.93 respectively, |△ Ct|=2.01±1.06; P =0.000). The mean of these three genes' Ct value is the most stable one analyzed by the two softwares. But the t test showed that the mean of Ct value of GUSB and β2-M is the unique combination that had the minimum intra-and inter-group difference, with no statistically significant differences between normal and malignant samples (The intra-and inter-group s is 0.53 and 0.79 respective]y, |△Ct|= 0.73±0.53; P =0.053). Conclusion It is inappropriate to normalize data derived from lung tissue specimens using one of these three housekeeping genes alone. Among the different combinations of these three genes, the mean of the Ct values of GUSB and β2-M is the best choice as the internal control of lung tissue specimens.